Cerise Raffier

Technical Specialist

+1 617 803 6778 +1 617 803 6778
cerise.raffier@finnegan.com cerise.raffier@finnegan.com

Two Seaport Lane
Boston, MA 02210-2001

vCard

Show Cerise's work in

Cerise Raffier leverages her technical background in chemistry and molecular biology to assist clients with patent prosecution matters within the biotechnology and pharmaceutical fields.

Before joining Finnegan, Cerise worked at the Center for the Development of Therapeutics (CDoT) at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard. She developed biochemical and biophysical assays to identify and optimize small molecules for therapeutic applications. Her research focused on identifying inhibitors for protein targets involved in various cancer types, collaborating with both academic and industrial partners.

Cerise possesses a broad range of technical expertise in biochemistry, including mass spectrometry-based assays, ligand binding assays, and enzymology. During her graduate studies, she gained experience in recombinant protein expression and enzyme engineering.

Et Cetera

Coauthor. "Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state," Nature Communications, 2022.

Experience

Comprehensive patent transactions and strategic counseling for one of the largest pharmaceutical companies in the world

Finnegan is lead and preferred IP transactions counsel for one of the largest pharmaceutical companies in the world, handling more than 50 diligence projects each year, including all IP and related transactional aspects of the matters. The transactions span the full gamut of technologies from small molecule through biologics such as antibodies, oligonucleotides, and gene therapies. Finnegan also provides extensive assistance with post-deal integration procedures and subsequent global prosecution and portfolio strategy, ensuring a seamless transition of IP assets to the company and maximum value from acquired IP.

Finnegan designed and prosecuted a global patent strategy with client Eisai on MORAb-202, an antibody-drug conjugate (ADC), providing pivotal support for Eisai’s exclusive, global strategic collaboration agreement with Bristol-Myers Squibb Company (BMS) to co-develop and co-commercialize the asset. Under the publicly announced financial terms of the agreement, BMS will pay Eisai $650 million, including $200 million as payment towards Eisai’s research and development expenses. Eisai is also entitled to receive up to $2.45 billion in potential future development, regulatory, and commercial milestones.